Sweden's Meda has signed a 120 million euro deal with Swiss giant Roche to acquire four of the latter's pharmaceutical products, which combined pull in some 500 million Swedish kroner (53.5 million euros) annually.

Specifically, the agreement gives Meda worldwide rights to the medicines - the anticoagulant Marcoumar (phenprocoumon), the diuretic Torem (torasemide), the non-steroidal anti-inflammatory Tilcotil (tenoxicam) and Aurorix (moclobemide), an antidepressant - bolstering its presence in the key therapeutic areas of cardiology, central nervous system and pain/inflammation.

It says the most important markets going forward are Germany, Spain, Switzerland, the USA, and France. Currently Marcoumar's biggest region in terms of revenues is Germany, with sales of 200 million kroner. Torem, which is also known under the trade names Demadex, Dilutol and Toradiur, is marketed in more than 30 countries currently, including the USA and Japan, with sales of 180 million kroner.

Tilcotil is indicated for inflammatory disorders of the musculoskeletal system, such as rheumatoid and osteoarthritis, pulling in 70 million kroner annually. Finally, Aurorox is a monoamine oxidase inhibitor with sales of 50 million kroner.

The revenues from four established brands will undoubtedly be a welcome boost to Meda's coffers, yet represent just 0.3% of the pharmaceuticals division’s sales for Roche. Divesting the products, says Roche, underlines its strategy of focusing on core products from its innovation-driven pharmaceutical and diagnostic pipelines.

The transaction is expected to close in late 2008.